| Document |
Document Title |
|
WO/2019/070018A1 |
Provided is a method with which it is possible to produce, easily and at excellent yield, a pyrrolidone carboxylic acid of extremely high chemical purity and optical purity or an alkali metal salt thereof. A method for producing an optic...
|
|
WO/2019/066289A1 |
The present invention relates to a compound represented by chemical formula 1, a preparation method therefor, and a modified conjugated diene-based polymer having a high modification ratio, containing a functional group derived from the ...
|
|
WO/2019/063696A1 |
The invention relates to primary para-phenylenediamine compounds substituted with an aliphatic chain comprising a cationic heterocyclic group according to formula (I), as well as the organic or mineral acid or base addition salts thereof...
|
|
WO/2019/065954A1 |
The present invention provides: a methyl 1-{2-[(3S, 4R)-1-[(3R, 4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-c
arbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethy
l)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-di...
|
|
WO/2019/067113A1 |
Described herein is an hydrofluorocarboximidate of formula (I) where: RH is a linear or branched alkyl group comprising 1 or 2 carbon atoms and (a) Rf1 and Rf2 are independently selected from a linear or branched perfluorinated alkyl gro...
|
|
WO/2019/062027A1 |
The present invention provides a green preparation method for N-substituted-L-pyroglutamic acid ester (I), comprising: using L-glutamic acid (II) as a starting material, and preparing L-glutamic acid diester hydrochloride (III) by means ...
|
|
WO/2019/059687A1 |
The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treati...
|
|
WO/2019/057158A1 |
Provided are a condensed heteroaryl derivative, a preparation method therefor, and application thereof in medicines. Specifically, provided are a condensed heteroaryl derivative represented by general formula (I), a preparation method th...
|
|
WO/2019/053425A1 |
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.
|
|
WO/2019/055590A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therape...
|
|
WO/2019/044739A1 |
A phosphor which is composed of a maleimide compound represented by general formula (1). (In the formula, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms or a halogen atom; A represents a substituted or unsubstitute...
|
|
WO/2019/042267A1 |
Disclosed in the present invention are a pyrrole-2-formamide compound, a preparation method therefor, a pharmaceutical composition thereof, and application thereof in the preparation of drugs for treating or preventing infective diseases...
|
|
WO/2019/042447A1 |
A novel toxin and a method for preparing an intermediate thereof. Specifically provided are a compound as represented by formula (III) and a method for preparing same, and a method for preparing a compound as represented by formula (I) w...
|
|
WO/2019/042301A1 |
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...
|
|
WO/2019/040105A2 |
The present disclosure relates to compounds according to Formula (I), treating diseases.
|
|
WO/2019/040106A2 |
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
|
|
WO/2019/040869A1 |
This invention relates to compounds for treating a protozoan parasitic infection and to pharmaceutical compositions comprising the compounds; and to methods of using the compounds and compositions to treat parasitic infections.
|
|
WO/2019/033330A1 |
Compounds of Formula (I) a or (I) b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these comp...
|
|
WO/2019/033219A1 |
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...
|
|
WO/2019/033590A1 |
Disclosed are a substituted benzoyl cyclohexanedione compound or a tautomer and salt thereof, a preparation method therefor, a herbicidal composition and the use. The substituted benzoyl cyclohexanedione compound or a tautomer and salt t...
|
|
WO/2019/033773A1 |
The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetr...
|
|
WO/2019/029598A1 |
A preparing method for high-purity levetiracetam, comprising: adjusting the pH of an extracted aqueous layer obtained by dissociating (S)-α-2-oxo-1-pyrrolidineacetic acid (R)- methylbenzylamine salt to 5-9; removing water; adding an org...
|
|
WO/2019/029211A1 |
Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof, and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmac...
|
|
WO/2019/029274A1 |
Provided in the present invention are a novel compound and a preparation method therefor. The general structural formula of the compound is shown as formula I. Animal experiments prove that the compound of the present invention has the e...
|
|
WO/2019/029273A1 |
A novel compound, a preparation method therefor and use thereof. The structure is as shown in formula I. Said compound can be used for preparing medicaments for treating diseases such as Alzheimer's disease, Parkinson's disease, vascular...
|
|
WO/2019/032632A1 |
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is -CH2- or -C(O)-; R1 is -OH or -OP(O)(OH)2; L is a bond, -CH2-, or -C(O)-; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and -CH3; and n is zero,...
|
|
WO/2019/030158A1 |
The present invention relates to cocrystalsof2-[(1R,6R)-6-isopropenyl-3-methylcyclohex- 2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purificatio...
|
|
WO/2019/028666A1 |
Disclosed is a method for preparing levetiracetam, comprising the following steps: performing resolution under the action of an ester hydrolase using 2-halobutyrate as a raw material to obtain (S)-2-halobutyrate, reacting with 2-pyrrolid...
|
|
WO/2019/028669A1 |
The present invention relates to a method for preparing levetiracetam, characterized by performing ammonolysis with liquid ammonia using (S)-α-ethyl-2-oxo-1-pyrrolidine acetate as a raw material under a solvent-free condition to obtain ...
|
|
WO/2019/028671A1 |
Provides is a method for preparing levetiracetam. The method comprises producing (R/S)-α-ethyl-2-oxo-1-pyrrolidine acetate under the action of an alkaline reagent using 2-bromobutyrate and 2-pyrrolidinone as raw materials, performing re...
|
|
WO/2019/032631A1 |
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is -OH or -OP(O)(OH)2; L1 is -CR3=N-O-CRaRa- or CRaR-O-N=CR3; L2 is a bond, -C(O)-, or S(O)2-;and R2, R3, Ra, m, and n are defined her...
|
|
WO/2019/028117A1 |
Provided herein are resins, or compounds, embraced by structure (I): where L is a covalent bond, a hydrocarbylene linker optionally having one or more hetero atoms, with or without any one or more of urethanes, ureas, amides, carbamoyls,...
|
|
WO/2019/028168A1 |
Materials and methods for generating protein-polymer conjugates on solid supports are provided herein. The methods can include, for example, reversibly immobilizing a protein on a solid support, modifying the protein by adding polymer su...
|
|
WO/2019/025156A1 |
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crop cultivation and/or as plant growth regulators for influencing the growth o...
|
|
WO/2019/028228A1 |
Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are di...
|
|
WO/2019/027003A1 |
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. In the present invention, a compound represented by formula (I) (in the formula, each symbol is as described in the specification) or ...
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/021608A1 |
The compound according to the present invention is represented by formula (1) [in formula (1), R1 is a C1-3 linear or branched alkyl group or a hydroxyl group; R2 is a 1-pyrrolyl group, a 2-pyrrolyl group, or a 3-pyrrolyl group]. The pre...
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2019/020726A1 |
The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl ha...
|
|
WO/2019/022426A1 |
The present invention relates to a method for preparing N-substituted maleimide and, more particularly, to a method for preparing N-substituted maleimide, comprising the steps of: a) reacting maleic anhydride with a primary amine in the ...
|
|
WO/2019/023453A1 |
The disclosed and/or claimed inventive concept(s) provides a complex of at least one halogen and a compound comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties. The disclosed and/or claimed inve...
|
|
WO/2019/021290A1 |
This invention is directed to a process for the preparation of glycopyrrolate tosylate comprising the step of reacting a halogen salt of glycopyrrolate with tosylic acid or a salt thereof in the presence of hydrogen peroxide and at least...
|
|
WO/2019/023553A1 |
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...
|
|
WO/2018/144620A9 |
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating d...
|
|
WO/2019/016745A1 |
Aspects of the present application relate to process for the preparation of Pyrrolidine derivatives useful as key intermediates for active ingredients. Specific aspects relate to alternate process for the preparation of Upadacitinib inte...
|
|
WO/2019/016269A1 |
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
|
|
WO/2019/008506A1 |
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...
|
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
|
WO/2019/007889A1 |
The invention relates to a method for improving the utilization of the production potential of transgenic plants by treating the plant with an effective amount of the compound of formula (la) as described herein.
|
